IP Library Granted Patent US 8,568,794
Granted Patent B2
US 8,568,794 · App. 11/659,713 · Granted Oct 29, 2013

Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassinoid-containing plant extracts

Inventors: Christian Diehl (Cordova, AR); Silvia Chami De Diehl (Cordova, AR)
Assignee: Life Science Investments, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,568,794
App. No.
11/659,713
Granted
Oct 29, 2013
Kind
B2
Abstract

Pharmaceutical or dermo-cosmetic compositions for topical and intravaginal application for treatment of human and veterinary affections caused by anaerobic organisms or parasites are provided comprising quassinoids or plant extracts containing these phytochemicals, in effective amounts. Such compositions can be administered topically or intravaginally to patients in need thereof in various pharmaceutical dosage forms.

Claims (5)

1. A method for treating vaginitis caused by Gardenerell vaginalis , the method comprising:

administering topically or intravaginally to a human or an animal in need of treatment of vaginitis a therapeutically effective amount of a composition consisting essentially of:

an active agent consisting essentially of at least one quassinoid selected from the group consisting of Brusatol, Ailanthinon, Simalikalactone D, Quassin, 15-desacaetylundulatone, Chaparrinone, 15β-heptylchaparrinone, Neoquassin, Isoquassin, Parain, Quassimarin, Quassinol, Quassol, 18-hydroxy-quassin, Ailantinol A, Ailantinol B, Ailantinol C, Ailantinol D, Ailantinol E, Ailantinol F, Ailantinol G, Bruceanol A, Bruceanol B, Bruceanol C, Bruceanol D, Bruceanol E, Bruceanol F, Bruceanol G, Bruceanol H, Picrasinol A, Picrasinol B, Picrasinol C, Picrasinol D, Bruceoside A, Bruceoside B, Bruceoside C, Picrasinoside A, Picrasinoside B, Picrasinoside C, Picrasinoside D, Picrasinoside E, Picrasinoside F, Picrasinoside G, Picrasinoside H, Eurycomanone, 2-acetylglaucarubine, 13,18-dehydroglaucarubine, Glaucarubinone, Glaucarubine, Holacanthone, 20-simarolide, Simarubolide, Dehydroquassin, Isoparain, Nigakilactone A, Norneoquassin, and Quassialactol; and

an optional dermo-cosmetically or pharmaceutically topically acceptable excipient.

2. The method of claim 1 , wherein the composition is applied to skin or to mucosa, the composition having a total concentration of quassinoid of between 0.001 μg/ml to 0.1 μg/ml in a dermo-cosmetically or pharmaceutically topically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2007
From: DIEHL, CHRISTIAN; CHAMI DE DIEHL, SILVIA
To: LIFE SCIENCE INVESTMENTS LIMITED
Reel/Frame 019452/0440 →
Continuity (1)
Related Publication 20080089958A1 · Apr 17, 2008